Today: 30 March 2026
MongoDB stock bounces in premarket after 6% slide; traders eye MongoDB.local and earnings clock
15 January 2026
2 mins read

MongoDB stock bounces in premarket after 6% slide; traders eye MongoDB.local and earnings clock

New York, Jan 15, 2026, 04:59 EST — Premarket

  • MongoDB (NASDAQ:MDB) climbed 1.3% in premarket trading, bouncing back from a 5.9% slide on Wednesday
  • High-growth software stocks have come under pressure as investors shift away from expensive tech
  • Later Thursday, the MongoDB.local event in San Francisco might shape the short-term outlook

Shares of MongoDB (NASDAQ:MDB) climbed 1.3% to $392.09 in early trading Thursday, clawing back some losses from the previous day. The database software company’s stock had closed 5.9% lower at $386.89 on Wednesday. Premarket trading occurs before U.S. markets open at 9:30 a.m. ET. Public

The stock has struggled through a volatile week. Since closing at $440.60 on Jan. 7, MongoDB has dropped roughly 12%. On Wednesday, its price swung between about $410 and $385, based on available data. StockAnalysis

That’s significant given MongoDB has stood out among large-cap software stocks, soaring roughly 97% in the past six months and recently hitting a 52-week peak at $444.72. A retreat from that high might trigger a larger correction if investors conclude the current valuation already factors in the next growth phase. Nasdaq

Expensive tech stocks took a hit as the Nasdaq dropped 1% on Wednesday, Reuters noted. Investors shifted out of pricey megacaps, favoring value and defensives instead. “Investors are looking to rotate out of expensive megacaps and into value and more defensive names,” said Michael O’Rourke, chief market strategist at JonesTrading. Reuters

MongoDB takes center stage Thursday with its MongoDB.local San Francisco general session at 10 a.m. PT, per the company’s events page. Investors are likely tuning in for product updates and new customer stories that might sway sentiment following the midweek slide.

On Jan. 13, MongoDB announced that Atlas Stream Processing now supports integration with Confluent’s Schema Registry for Avro message formats, targeting teams that handle data through Kafka-like pipelines. Atlas is MongoDB’s cloud database service, and stream processing enables developers to work with data in real time rather than relying on batch jobs.

The pitch is familiar: store more of the data stack within MongoDB’s platform and simplify building real-time apps for customers. For investors, it boils down to whether Atlas usage keeps growing within enterprise budgets that remain under close scrutiny.

Analyst sentiment remains largely positive even as the stock cools off. On Jan. 12, Barclays’ Raimo Lenschow bumped his price target for MongoDB to $480 from $415, maintaining an Overweight rating, according to a note reported by TheFly. He pointed to “macro and IT spending are stable” while outlining the company’s 2026 software outlook. TipRanks

MongoDB reported third-quarter revenue of $628.3 million on Dec. 1, marking a 19% increase from the previous year. Atlas revenue jumped 30%, now representing 75% of the company’s total. The firm added roughly 2,600 customers, pushing the total beyond 62,500 by Oct. 31. PR Newswire

The downside is clear-cut. MongoDB’s consumption-based cloud model can slow sharply if clients cut back on usage, and with its premium valuation, there’s little margin for error. Competition remains fierce, from hyperscalers’ own database offerings to rival data platforms targeting those workloads.

The next question is whether management can leverage Thursday’s event to stabilize the story and prevent the premarket gains from slipping once the market opens. Wall Street is eyeing the next earnings report around March 4, although the company hasn’t officially set a date, per Zacks’ earnings calendar. That report — along with any updates on Atlas growth and customer spending — is the key catalyst traders are watching. Zacks

Stock Market Today

  • 1 Stock to Buy and 2 to Avoid Near 52-Week Highs: United Therapeutics Shines, Tilly's and Bristol-Myers Squibb Falter
    March 30, 2026, 9:49 AM EDT. Stocks near their 52-week highs often reflect strong momentum, but not all sustain success. United Therapeutics (NASDAQ: UTHR) stands out with 16.9% revenue growth, a robust 34.2% free cash flow margin, and improving capital returns, signaling solid market positioning. Conversely, Tilly's (NYSE: TLYS) posts a 197% one-month gain but struggles with decreasing same-store sales and a 55.2% annual drop in earnings per share (EPS), raising valuation concerns at a forward EV-to-EBITDA of 92.6x. Bristol-Myers Squibb (NYSE: BMY) faces growth constraints with only 2.6% revenue increase over five years and shrinking operating margins, trading at 9.5x forward price-to-earnings (P/E). Investors should weigh United Therapeutics' fundamentals against challenges in Tilly's and BMY before acting.
ROLR stock: High Roller holds premarket after 437% surge on Crypto.com prediction-markets plan
Previous Story

ROLR stock: High Roller holds premarket after 437% surge on Crypto.com prediction-markets plan

Rivian stock slips in premarket after UBS turns bearish — what could move RIVN next
Next Story

Rivian stock slips in premarket after UBS turns bearish — what could move RIVN next

Go toTop